At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HSCS Heart Test Laboratories, Inc.
Pre-Market Trading 05-10 07:23:16 EDT
0.0899
+0.0009
+1.01%
High0.0917Low0.0872Vol934.16K
Open0.0900D1 Closing0.0890Amplitude5.06%
Mkt Cap5.89MTradable Cap5.06MTotal Shares65.56M
T/O83.09KT/O Rate1.66%Tradable Shares56.25M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
GlobeNewswire  ·  04-24
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
GlobeNewswire  ·  03-26
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
SaucerSwap increases total value locked by 300 percent in just one year with support from The Hashgraph Association (THA)
StreetInsider  ·  03-21
SaucerSwap increases total value locked by 300 percent in just one year with support from The Hashgraph Association (THA)
Heart Test Laboratories Third Quarter 2024 Earnings: US$0.031 loss per share (vs US$0.16 loss in 3Q 2023)
Simply Wall St.  ·  03-16
Heart Test Laboratories Third Quarter 2024 Earnings: US$0.031 loss per share (vs US$0.16 loss in 3Q 2023)
Heart Test Laboratories Cash And Cash Equivalents As Of Jan. 31 Were ~$7.1M
Benzinga  ·  03-15
Heart Test Laboratories Cash And Cash Equivalents As Of Jan. 31 Were ~$7.1M
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
GlobeNewswire  ·  03-15
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
GlobeNewswire  ·  03-12
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
Dow Jumps 200 Points; Abercrombie & Fitch Posts Upbeat Profit
Benzinga  ·  03-06
Dow Jumps 200 Points; Abercrombie & Fitch Posts Upbeat Profit
Heart Test Labs Shareholders Approve Quorum Amendment
TIPRANKS  ·  02-16
Heart Test Labs Shareholders Approve Quorum Amendment
Heart Test Laboratories Shareholders Annual Voting Outcomes
TIPRANKS  ·  01-19
Heart Test Laboratories Shareholders Annual Voting Outcomes

Introduction

Company Name.
Heart Test Laboratories, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Issue price:
--